The FLT3 inhibitors quizartinib and crenolanib and the pan-TK inhibitor ponatinib (0.1 μM) were able to reduce the proliferation rate of primary B-NEG ALL cells from 3 patients carrying FLT3 ITD mutations and 1 harboring a TKD mutation: indeed, after 72 hours of treatment, quizartinib reduced the percentage of proliferating cells to 28.3±9%, crenolanib to 29.5±21.1% and ponatinib to 20.7±7% (Figure 8A). The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.